4,901 trials
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Solicited Local Adverse Events (AE) During 7 Days After Vaccination — 5; 9; 16; 19 Participants
Gastrointestinal Cancer, Metastatic
Primary: Determination of the Maximum Tolerated Dose (MTD) of BI 905711 — NA milligram / kilogram (mg/kg)
Glioblastoma Multiforme · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs) — 3 Participants
Hypercholesterolaemia
Primary: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of Enlicitide Decanoate — 733; 554; 850; 570 hr*nmol/Liter
End Stage Renal Disease on Hemodialysis
Primary: Evaluation of the PK Profile of Difelikefalin - Cmax - Dose 1 — 3.70 ng/mL
Locally Advanced Pancreatic Ductal Adenocarcinoma · Metastatic Pancreatic Ductal Adenocarcinoma
Primary: Incidence of Grade 3 or 4 Adverse Events — 2; 8 Participants
COVID-19 Disease · SARS Pneumonia · Pneumonia, Viral
Primary: Solicited Adverse Events — 88.0; 68.0; 88.0; 80.0 percent of participants
Healthy
Primary: Gonadotropin Suppression — 16; 1 Participants — p=0.003
Pulmonary Arterial Hypertension · Familial Primary Pulmonary Hypertension · Primary Pulmonary Hypertension
Primary: Plasma Carnitine Concentration — 44 uM
Cystic Fibrosis
Primary: Decrease in FEV0.5 After Inhalation of Hypertonic Saline — 0 participants
Opioid Use Disorder
Primary: Percent of Radioactive Dose Excreted in the Urine, Feces, and Urine+Feces (%Dose) Following a Single Oral Dose of [14C]-IDV184001AN in Healthy Adult Male Participants…
Prostatic Neoplasms
Primary: Change in Area Under the Plasma Concentration 0-8Hour (Hr)(AUC0-8hr) Values in Males Between Pre-Androgen Deprivation Therapy (ADT) and Post-ADT — 484.65; 473.05 Hr*ng/mL
Healthy Participants
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Etrasimod — 1620; 1529; 1538; 1391…
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 3; 2; 2; 3 Participants
Elevated Serum Lipoprotein(a)
Primary: Maximum Observed Concentration (Cmax) of Olpasiran — 144; 549 ng/mL